Document is current
Any future updates will be listed below
-
Authors
Xu, Yingxi https://orcid.org/0000-0002-0056-7440
Shangguan, Yangtao
Chuang, Yu-Ming
Chang, Tzu-Hsuan https://orcid.org/0000-0003-0455-3107
Liu, Wenbing https://orcid.org/0000-0003-4562-5541
Peng, Jhan-Jie
Garnica, Josep https://orcid.org/0000-0001-9493-1321
Xie, Leling
Hsueh, Pei-Chun
Lin, Mei-Chun
Wang, Yi-Hao https://orcid.org/0009-0004-3972-4206
Hajdu, Karina Lobo https://orcid.org/0000-0001-9655-3870
Wu, Yibo
Akrami, Maryam https://orcid.org/0000-0001-6450-8442
Wang, Chen https://orcid.org/0000-0003-2271-5587
Kohl, Anna
Zippelius, Alfred https://orcid.org/0000-0003-1933-8178
Qi, Wei
Wang, Min
Budiarto, Bugi Ratno
Chen, Shih-Yu https://orcid.org/0000-0002-7955-481X
Xiao, Zhengtao
Vardaka, Panagiota
Roychoudhuri, Rahul https://orcid.org/0000-0002-5392-1853
Bai, Zhiliang https://orcid.org/0000-0002-3977-3057
Fan, Rong https://orcid.org/0000-0001-7805-8059
Carmona, Santiago https://orcid.org/0000-0002-2495-0671
Yu, Yi-Ru
Scheiermann, Christoph https://orcid.org/0000-0002-9212-0995
Wang, Jianxiang https://orcid.org/0000-0001-9437-9151
Ho, Ping-Chih https://orcid.org/0000-0003-3078-3774
- License Information
-
More Information
Article History
Received: 24 June 2024
Accepted: 6 February 2026
First Online: 18 March 2026
Competing interests
: P.-C. Ho is the co-founder of Pilatus Biosciences. A.Z. received consulting/advisor fees from Bristol-Myers Squibb, Merck Sharp & Dohme, Hoffmann–La Roche, NBE Therapeutics and Engimmune, and maintains further non-commercial research agreements with Hoffmann–La Roche, T3 Pharma, Bright Peak Therapeutics and AstraZeneca. R.R. holds or has held paid consultancies with Lyell Immunopharma, Achilles Therapeutics and Enhanc3D Genomics; and is a principal investigator of research projects funded by AstraZeneca and F-star Therapeutics on unrelated topics that do not constitute competing interests. The other authors declare no competing interests.
